Associated Papers
Deep mutational scanning of a multi-domain signaling protein reveals mechanisms of regulation and pathogenicity.
Jiang Z et al.
Biorxiv : the Preprint Server for Biology, 2024
39091798 (PubMed )
Supplement: media-4.xlsx › SHP2-PTP_cSrc-KD_column
Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers.
Miao Y et al.
The Journal of Clinical Investigation, 2024
Setting sail: Maneuvering SHP2 activity and its effects in cancer.
Welsh CL et al.
Advances in Cancer Research, 2023
Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.
Shen D et al.
European Journal of Medicinal Chemistry, 2020
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX et al.
Molecular Cancer Therapeutics, 2019
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.
Fedele C et al.
Cancer Discovery, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ et al.
Nature Cell Biology, 2018
Dual Allosteric Inhibition of SHP2 Phosphatase.
Fodor M et al.
Acs Chemical Biology, 2018
Targeting endogenous proteins for degradation through the affinity-directed protein missile system.
Fulcher LJ et al.
Open Biology, 2017
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN et al.
Nature, 2016
Select a paper to view details